Krystal Biotech Inc. (KRYS) has been on a tear since securing FDA approval for its first product on May 19.
Vyjuvek, a topical gel approved for the treatment of dystrophic epidermolysis bullosa, is not only the first FDA-approved product for the company but is also the first-ever redosable gene therapy and the first and only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa, both recessive and dominant.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com